HLL Biotech Ltd, a subsidiary of public sector HLL Lifecare Ltd, has entered into a long term supply and technology licence agreement with the Institute of Immunology, Zagreb, Croatia, for the manufacture of measles vaccine in India.

The agreement was signed between M Ayyappan, Chairman & Managing Director, HLL Lifecare Ltd and Davorin Gajnik, Director, IMZ in the presence of Ivan Vrdoljak, Croatia’s Minister for Economy, in Zagreb on August 20 last.

Under the partnership agreement, IMZ will transfer the technology to manufacture bulk measles vaccine to HBL.

Initially, for the first two years, IMZ will supply the bulk of measles vaccine to HBL, which will be formulated and filled at the facility of HBL in India.

Set up in 1893, the Institute of Immunology, Zagreb, is one of the world’s oldest manufacturers of immunobiological medicines.

It is a vaccine manufacturing and research facility of the Croatian government and a premier provider for measles vaccine strains in most parts of the world.

“Our agreement with IMZ is the first major project milestone of HBL’s vaccine technology collaboration intending to help protect children in India and other developing markets from measles,” Ayyappan, who is also the Chairman of HBL, said here today.

“Measles is a highly contagious viral disease and remains an important cause of death among young children globally. The Fourth Millennium Development Goal (MDG 4) aims to reduce the under-five mortality rate by two-thirds between 1990 and 2015, he said”.

*

HLL Biotech, Croatian institute, HLL Lifecare, technology licence agreement, Institute of Immunology, Zagreb Croatia, measles vaccine, M Ayyappan, Davorin Gajnik

comment COMMENT NOW